Figure S5 from BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer [PDF]
, 2023 Sun Min Lim +9 more
openalex +1 more source
MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. [PDF]
, 2013 PurposeMET alterations including amplifications and nucleotide variations have been associated with resistance to therapy and aggressive clinical behavior.Experimental designThe medical records of patients presenting to the University of Texas MD ...
De Melo Galgiato, Debora +13 more
core +3 more sources
Advanced Functional Materials, EarlyView.Zr‐Fe MOF@Ribociclib@Herceptin (ZFRH) efficiently targets/kills Human Epidermal Growth Factor Receptor 2/Estrogen Receptor‐positive (HER2/ER+) breast cancer cells. It combats tumors by: 1) Elevating ROS, altering redox balance; 2) Inhibiting transcription; 3) Inducing pyroptosis.
Hongkun Miao +8 more
wiley +1 more source
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]
, 2019 A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core +2 more sources
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Advanced Functional Materials, EarlyView.Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source
Clinical Medicine Insights: Oncology, 2011 The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase.
Marie P. Shieh +2 more
doaj +1 more source
Hematology Reports, 2014 We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well
David Sanford +3 more
doaj +1 more source
Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations [PDF]
, 2011 Tommaso De Pas +10 more
openalex +1 more source
Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to VEGF-R tyrosine kinase inhibition [PDF]
, 2009 This paper was presented at the 2nd Micro and Nano Flows Conference (MNF2009), which was held at Brunel University, West London, UK. The conference was organised by Brunel University and supported by the Institution of Mechanical Engineers, IPEM, the ...
2nd Micro and Nano Flows Conference (MNF2009) +7 more
core